Literature DB >> 11437187

Stroke in children with sickle cell anaemia: aetiology and treatment.

C H Pegelow1.   

Abstract

Cerebral infarction is a frequent, severe complication of sickle cell anaemia. During childhood, most strokes are due to infarction with the majority resulting from occlusion of the large cerebral arteries. Risk factors include transient ischaemic attacks, acute chest syndrome, severe anaemia and elevated blood pressure. Less certain is the association with leucocytosis, or protection provided by alpha-thalassaemia or fetal haemoglobin. Children who have one stroke are at significant risk for having subsequent events that can be substantially reduced by maintaining haemoglobin S below 30%. It has not yet been possible to identify individuals for whom transfusion can be safely stopped. Haemosiderosis is a consequence of intensive and long term transfusion therapy, which requires chelation with deferoxamine. Iron accumulation can be minimised using erythrocytapheresis but this is technically difficult in children, expensive and results in increased donor exposure. In addition to lesions associated with strokes, an additional 17% of patients can be shown to have clinically silent cerebral infarcts. Although these are termed 'silent', those affected have mild neuropsychological deficits. Their relationship to stroke or risk for recurrence is unknown. Transfusion therapy has been shown to provide primary stroke prevention for children who have elevated cerebral artery velocity. Finally, intracranial haemorrhages, more commonly found in adults, also affect children. Subarachnoid haemorrhage is frequently found to result from cerebral artery aneurysms. A condition that mimics the moyamoya syndrome radiographically, as well as for its risk of haemorrhage, can be found in children with partly occluded cerebral arteries either as a result of stroke or silent infarct.

Entities:  

Mesh:

Year:  2001        PMID: 11437187     DOI: 10.2165/00128072-200103060-00003

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  96 in total

1.  Studies on the destruction of red blood cells. VIII. Molecular orientation in sickle cell hemoglobin solutions.

Authors:  J W HARRIS
Journal:  Proc Soc Exp Biol Med       Date:  1950-10

2.  Neurologic events after partial exchange transfusion for priapism in sickle cell disease.

Authors:  W R Rackoff; K Ohene-Frempong; S Month; J P Scott; B Neahring; A R Cohen
Journal:  J Pediatr       Date:  1992-06       Impact factor: 4.406

3.  Neurological manifestations in sickle-cell disease, with a review of the literature and emphasis on the prevalence of hemiplegia.

Authors:  B A Portnoy; J C Herion
Journal:  Ann Intern Med       Date:  1972-04       Impact factor: 25.391

4.  Occlusion of large cerebral vessels in sickle-cell anemia.

Authors:  J A Stockman; M A Nigro; M M Mishkin; F A Oski
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

5.  Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia.

Authors:  R E Ware; M H Steinberg; T R Kinney
Journal:  Am J Hematol       Date:  1995-10       Impact factor: 10.047

6.  Computerized tomography complications.

Authors:  C Imbus; D Powars; C Pegelow; H D Segall
Journal:  Arch Neurol       Date:  1978-09

7.  Moyamoya in children with sickle cell anemia and cerebrovascular occlusion.

Authors:  R A Seeler; J E Royal; L Powe; H R Goldberg
Journal:  J Pediatr       Date:  1978-11       Impact factor: 4.406

8.  Alpha thalassemia and stroke risk in sickle cell anemia.

Authors:  R J Adams; A Kutlar; V McKie; E Carl; F T Nichols; J C Liu; K McKie; A Clary
Journal:  Am J Hematol       Date:  1994-04       Impact factor: 10.047

9.  Reassessment of the use of desferrioxamine B in iron overload.

Authors:  R D Propper; S B Shurin; D G Nathan
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

10.  Nontraumatic fat embolism syndrome in sickle cell anemia.

Authors:  D P Horton; D M Ferriero; W C Mentzer
Journal:  Pediatr Neurol       Date:  1995-01       Impact factor: 3.372

View more
  2 in total

1.  Treatment and prevention of stroke in children with sickle cell disease.

Authors:  Shyamal H Mehta; Robert J Adams
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.972

2.  Characterization of inpatient moyamoya in the United States: 1988-2004.

Authors:  Darrin J Lee; David S Liebeskind
Journal:  Front Neurol       Date:  2011-07-04       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.